

Carsten M¹/₄ller-Tidow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5825390/publications.pdf>

Version: 2024-02-01

506
papers

20,231
citations

14655

66
h-index

17105

122
g-index

516
all docs

516
docs citations

516
times ranked

27194
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. <i>Blood</i> , 2022, 139, 87-103.	1.4	82
2	Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. <i>Blood</i> , 2022, 139, 142-147.	1.4	63
3	<sc>CD33</sc>-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and <sc>CD33</sc>-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. <i>International Journal of Cancer</i> , 2022, 150, 1141-1155.	5.1	13
4	Differential impact of <i>IDH1</i>/<i>2</i> mutational subclasses on outcome in adult AML: results from a large multicenter study. <i>Blood Advances</i> , 2022, 6, 1394-1405.	5.2	17
5	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. <i>Leukemia</i> , 2022, 36, 913-922.	7.2	23
6	Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 903.	4.1	7
7	Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. <i>Haematologica</i> , 2022, 107, 1891-1901.	3.5	15
8	HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma. <i>Biomedicines</i> , 2022, 10, 373.	3.2	2
9	Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement. <i>PLoS ONE</i> , 2022, 17, e0264407.	2.5	10
10	Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation. <i>Vaccines</i> , 2022, 10, 330.	4.4	9
11	Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2337.	4.1	1
12	Ageing and interferon gamma response drive the phenotype of neutrophils in the inflamed joint. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 805-814.	0.9	11
13	Targeted siRNA nanocarrier: a platform technology for cancer treatment. <i>Oncogene</i> , 2022, 41, 2210-2224.	5.9	16
14	CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia. <i>EMBO Molecular Medicine</i> , 2022, 14, e14990.	6.9	14
15	Comparison of single copy gene-based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19-directed CAR T cells in treated patients. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	5
16	Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML. <i>Blood Advances</i> , 2022, 6, 3294-3303.	5.2	11
17	Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD. <i>Frontiers in Oncology</i> , 2022, 12, 862991.	2.8	1
18	EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study. <i>Frontiers in Immunology</i> , 2022, 13, 877477.	4.8	17

#	ARTICLE	IF	CITATIONS
19	Validation of a proxy-reported SARC-F questionnaire for current and retrospective screening of sarcopenia-related functional impairments. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 264-275.	7.3	6
20	Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2022, 101, 681-691.	1.8	12
21	Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation. <i>Intensive Care Medicine</i> , 2022, 48, 753-755.	8.2	10
22	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. <i>Journal of Hematology and Oncology</i> , 2022, 15, 60.	17.0	17
23	Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. <i>Cell Stem Cell</i> , 2022, 29, 760-775.e10.	11.1	29
24	A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	4
25	Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. <i>Annals of Hematology</i> , 2021, 100, 2087-2093.	1.8	29
26	Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel. <i>Haematologica</i> , 2021, 106, 446-453.	3.5	38
27	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranilcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. <i>Leukemia</i> , 2021, 35, 701-711.	7.2	56
28	The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 30-37.	2.4	5
29	The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. <i>International Journal of Cancer</i> , 2021, 148, 150-160.	5.1	10
30	Comments on "Cost of decentralized CAR T cell production in an academic non-profit setting". <i>International Journal of Cancer</i> , 2021, 148, 514-515.	5.1	4
31	Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLapsE. <i>Leukemia</i> , 2021, 35, 1134-1144.	7.2	36
32	Ibrutinib for improved chimeric antigen receptor T cell production for chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2021, 148, 419-428.	5.1	42
33	NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration. <i>Oncogene</i> , 2021, 40, 909-921.	5.9	34
34	HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 367-378.	4.1	42
35	Ruxolitinib is effective in the treatment of a patient with refractory T-ALL. <i>EJHaem</i> , 2021, 2, 139-142.	1.0	4
36	Cryostorage to What End? "Autologous Stem Cell Products in Burkitt Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Myeloproliferative Neoplasm Patients. <i>Transfusion Medicine and Hemotherapy</i> , 2021, 48, 91-98.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*. British Journal of Haematology, 2021, 192, 832-842.	2.5	15
38	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia, 2021, 35, 2517-2525.	7.2	40
39	Comparison of Open-access Databases for Clinical Variant Interpretation in Cancer: A Case Study of MDS/AML. Cancer Genomics and Proteomics, 2021, 18, 157-166.	2.0	6
40	Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD. Blood Cancer Journal, 2021, 11, 42.	6.2	5
41	Selective elimination of immunosuppressive T cells in patients with multiple myeloma. Leukemia, 2021, 35, 2602-2615.	7.2	27
42	EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity. Leukemia, 2021, 35, 1521-1526.	7.2	3
43	Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. Nature Communications, 2021, 12, 1366.	12.8	69
44	CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood, 2021, 138, 318-330.	1.4	98
45	Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers, 2021, 13, 2095.	3.7	7
46	Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma. Cancers, 2021, 13, 1684.	3.7	17
47	Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy. Frontiers in Immunology, 2021, 12, 670088.	4.8	10
48	Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study. Haematologica, 2021, 106, 3100-3106.	3.5	14
49	<sc>Daratumumab, lenalidomide, and dexamethasone</sc> in systemic <sc>lightâ€chain</sc> amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21. American Journal of Hematology, 2021, 96, E253-E257.	4.1	13
50	C/EBPÎ² is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia. Oncogene, 2021, 40, 4746-4758.	5.9	14
51	Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. Nature Cancer, 2021, 2, 527-544.	13.2	37
52	CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues. Blood, 2021, 138, 1067-1080.	1.4	29
53	Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19. Journal of Clinical Virology, 2021, 139, 104847.	3.1	37
54	Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19â€positive malignancies. Oncology Reports, 2021, 46, .	2.6	12

#	ARTICLE	IF	CITATIONS
55	Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Cancers</i> , 2021, 13, 3439.	3.7	5
56	Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up. <i>British Journal of Haematology</i> , 2021, 195, 230-243.	2.5	11
57	Submyeloablative total body irradiation-based conditioning and allogeneic stem cell transplantation in high-risk myeloma with early progression after upfront autologous transplantation. <i>British Journal of Haematology</i> , 2021, , .	2.5	1
58	Impact of <i>PTPN11</i> mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 3279-3289.	5.2	21
59	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4706.	3.7	11
60	Phagocytosis by stroma confounds coculture studies. <i>IScience</i> , 2021, 24, 103062.	4.1	2
61	Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression. <i>Nature Genetics</i> , 2021, 53, 1443-1455.	21.4	19
62	An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies. <i>Blood Advances</i> , 2021, 5, 5060-5071.	5.2	9
63	Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 876.e1-876.e11.	1.2	8
64	Early bilirubinemia after allogeneic stem cell transplantation—an endothelial complication. <i>Bone Marrow Transplantation</i> , 2021, 56, 1573-1583.	2.4	10
65	Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells. <i>Cells</i> , 2021, 10, 152.	4.1	2
66	Acquisition and Transmission of Carbapenemase-Producing (<i>KPC-2</i>) <i>Enterobacter cloacae</i> in a Highly Frequented Outpatient Clinic. <i>Clinical Infectious Diseases</i> , 2021, 72, e158-e161.	5.8	8
67	Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease. <i>Cell Reports Medicine</i> , 2021, 2, 100409.	6.5	11
68	Epitranscriptomic modifications in acute myeloid leukemia: m ⁶ A and 2 ^o -methylation as targets for novel therapeutic strategies. <i>Biological Chemistry</i> , 2021, 402, 1531-1546.	2.5	3
69	Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. <i>Trials</i> , 2021, 22, 765.	1.6	2
70	P-188: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S140-S141.	0.4	0
71	Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience. <i>Blood</i> , 2021, 138, 3370-3370.	1.4	1
72	Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries. <i>Blood</i> , 2021, 138, 872-872.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Sensitivity and Specificity of CD19-CAR-T Cell Detection by Flow Cytometry and PCR. <i>Cells</i> , 2021, 10, 3208.	4.1	13
74	Multi-Modality Imaging Reveals Structural Centrosome Aberrations As a Potential Driver of Chromosomal Instability in Early-Stage Plasma Cell Disorders. <i>Blood</i> , 2021, 138, 1579-1579.	1.4	0
75	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021, 21, 1170.	2.9	46
76	Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. <i>Nature Communications</i> , 2021, 12, 6960.	12.8	53
77	Six-Month Follow-up for Infectious Complications after Lymphodepletion and Application of CD19-Chimeric Antigen Receptor T (CAR-T) Cell Therapy. <i>Blood</i> , 2021, 138, 4835-4835.	1.4	1
78	Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states. <i>Nature Immunology</i> , 2021, 22, 1577-1589.	14.5	76
79	The Spatial Heterogeneity in Newly Diagnosed Multiple Myeloma Patients - from Sub-Clonal Architecture to the Immune Microenvironment. <i>Blood</i> , 2021, 138, 729-729.	1.4	3
80	Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4. <i>Blood</i> , 2021, 138, 1307-1307.	1.4	0
81	Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial). <i>Blood</i> , 2021, 138, 1734-1734.	1.4	1
82	Randomized Phase II Study of All- <i>Trans</i> Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of <i>TP53</i> Status. <i>Blood</i> , 2021, 138, 2380-2380.	1.4	2
83	Easix Predicts Severe Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neuro-Toxicity Syndrome (ICANS) in Patients Receiving CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy. <i>Blood</i> , 2021, 138, 3861-3861.	1.4	1
84	Leukemic Stem Cells of Monocytic AMLs Are Not-Resistant to BCL-2 Inhibition. <i>Blood</i> , 2021, 138, 3469-3469.	1.4	1
85	Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study. <i>Blood</i> , 2021, 138, 4418-4418.	1.4	3
86	Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD). <i>Blood</i> , 2021, 138, 1810-1810.	1.4	0
87	Prediction of Complete Remission and Survival in Acute Myeloid Leukemia Using Supervised Machine Learning. <i>Blood</i> , 2021, 138, 108-108.	1.4	1
88	Two-Year Evaluation of the German Clinical Amyloidosis Registry. <i>Blood</i> , 2021, 138, 3780-3780.	1.4	3
89	OAB-007: Single-cell multiomic analysis identifies regulatory programs in relapsed/refractory multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S5.	0.4	0
90	P-049: The spatial sub-clonal architecture in newly diagnosed myeloma patients revealed by whole genome and single-cell sequencing. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S65.	0.4	0

#	ARTICLE	IF	CITATIONS
91	The onset of active disease in systemic lupus erythematosus patients is characterised by excessive regulatory CD4+T-cell differentiation. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 279-288.	0.8	3
92	Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas. <i>Biomedicines</i> , 2021, 9, 1842.	3.2	6
93	Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia. <i>Scientific Reports</i> , 2021, 11, 23280.	3.3	1
94	The onset of active disease in systemic lupus erythematosus patients is characterised by excessive regulatory CD4+T-cell differentiation. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 279-288.	0.8	5
95	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. <i>Haematologica</i> , 2020, 105, 161-169.	3.5	15
96	Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice. <i>Leukemia</i> , 2020, 34, 721-734.	7.2	6
97	BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials. <i>Leukemia</i> , 2020, 34, 1454-1457.	7.2	16
98	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 257-270.	1.6	63
99	A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 828.	1.6	16
100	Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR. <i>Cancers</i> , 2020, 12, 2820.	3.7	13
101	CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease. <i>Transplantation</i> , 2020, 104, 2354-2359.	1.0	13
102	Interleukin-18 and Hematopoietic Recovery after Allogeneic Stem Cell Transplantation. <i>Cancers</i> , 2020, 12, 2789.	3.7	7
103	Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes. <i>Cancers</i> , 2020, 12, 2704.	3.7	13
104	Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. <i>Cancers</i> , 2020, 12, 2322.	3.7	15
105	CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison. <i>Blood Advances</i> , 2020, 4, 6157-6168.	5.2	26
106	Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 608167.	4.8	23
107	Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile. <i>Cancers</i> , 2020, 12, 3683.	3.7	1
108	EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e228-e231.	3.5	29

#	ARTICLE	IF	CITATIONS
109	Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. <i>Blood</i> , 2020, 135, 1517-1530.	1.4	67
110	Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1575-1580.	2.0	20
111	Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels. <i>Nature Cell Biology</i> , 2020, 22, 896-906.	10.3	93
112	Pre-transplant testosterone and outcome of men after allogeneic stem cell transplantation. <i>Haematologica</i> , 2020, 105, 1454-1464.	3.5	2
113	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. <i>Blood</i> , 2020, 136, 823-830.	1.4	85
114	Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1589-1596.	2.0	6
115	Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells. <i>Blood</i> , 2020, 136, 1507-1519.	1.4	57
116	Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 448-454.	4.1	28
117	Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. <i>American Journal of Hematology</i> , 2020, 95, 1158-1169.	4.1	25
118	High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience. <i>Annals of Hematology</i> , 2020, 99, 855-866.	1.8	6
119	AMLVaran: a software approach to implement variant analysis of targeted NGS sequencing data in an oncological care setting. <i>BMC Medical Genomics</i> , 2020, 13, 17.	1.5	4
120	B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. <i>International Journal of Cancer</i> , 2020, 147, 2029-2041.	5.1	10
121	Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution. <i>BMC Cancer</i> , 2020, 20, 353.	2.6	0
122	Phase I trial of donor-derived modified immune cell infusion in kidney transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 2364-2376.	8.2	29
123	Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial. <i>Blood</i> , 2020, 136, 1-3.	1.4	4
124	Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells. <i>Blood</i> , 2020, 136, 33-34.	1.4	11
125	Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation. <i>Blood</i> , 2020, 135, 2059-2070.	1.4	52
126	A Severe Case of Anaplastic Large Cell Lymphoma in a Previously Healthy Woman: Diagnostic and Therapeutic Challenges. <i>Prague Medical Report</i> , 2020, 121, 262-266.	0.8	1

#	ARTICLE	IF	CITATIONS
127	Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
128	The Bone Marrow Microenvironment of Multiple Myeloma Long-Term Survivors at Single Cell Resolution. <i>Blood</i> , 2020, 136, 32-33.	1.4	2
129	Prevalence of Inherited Predisposition Syndromes in Young Patients with Acute Myeloid Leukemia and Aberrant Karyotype. <i>Blood</i> , 2020, 136, 41-42.	1.4	0
130	The Ribomethylome Landscape of Hematopoietic System. <i>Blood</i> , 2020, 136, 41-42.	1.4	1
131	Molecular Subgroups of T Cell Acute Lymphoblastic Leukemia in Adults Treated According to GMALL Protocols. <i>Blood</i> , 2020, 136, 37-38.	1.4	4
132	Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 1018-1021.	2.5	21
133	Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma. <i>ESC Heart Failure</i> , 2019, 6, 824-829.	3.1	14
134	NPM1 functions in epitranscriptomics. <i>Nature Genetics</i> , 2019, 51, 1436-1437.	21.4	2
135	Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients. <i>Blood Cancer Journal</i> , 2019, 9, 13.	6.2	6
136	Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. <i>Haematologica</i> , 2019, 104, 1451-1459.	3.5	29
137	Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis. <i>Haematologica</i> , 2019, 104, e304-e306.	3.5	9
138	Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1195-1209.	4.2	27
139	The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2830-2841.	7.2	30
140	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. <i>BMJ Open</i> , 2019, 9, e026644.	1.9	27
141	Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2469.	4.1	14
142	Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. <i>Blood</i> , 2019, 134, 263-276.	1.4	41
143	Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. <i>Cytotherapy</i> , 2019, 21, 566-578.	0.7	23
144	Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML). <i>Annals of Hematology</i> , 2019, 98, 1393-1401.	1.8	10

#	ARTICLE	IF	CITATIONS
145	Shaping of CD56 ^{bri} Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis. <i>Frontiers in Immunology</i> , 2019, 10, 547.	4.8	16
146	Idelalisib for optimized CD19 ^{hi} -specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2019, 145, 1312-1324.	5.1	67
147	Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML). <i>Journal of Clinical Medicine</i> , 2019, 8, 200.	2.4	80
148	IRE1 α maintains HSC stemness under ER-stress. <i>Nature Cell Biology</i> , 2019, 21, 297-298.	10.3	4
149	Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApSE. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e286-e287.	0.4	0
150	Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study. <i>EBioMedicine</i> , 2019, 49, 202-212.	6.1	11
151	What's new in consolidation therapy in AML?. <i>Seminars in Hematology</i> , 2019, 56, 96-101.	3.4	10
152	A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 583-587.	2.5	5
153	Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2019, 12, 8.	17.0	38
154	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e128-e140.	2.0	40
155	Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation. <i>Haematologica</i> , 2019, 104, 827-834.	3.5	4
156	Cell-based immunotherapy approaches for multiple myeloma. <i>British Journal of Cancer</i> , 2019, 120, 38-44.	6.4	30
157	Collection, Cryostorage, Transplantation, and Disposal of Hematopoietic Stem Cell Products. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 382-390.	2.0	8
158	Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 13-13.	1.4	16
159	Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration. <i>Blood</i> , 2019, 134, 2693-2693.	1.4	2
160	Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease. <i>Blood</i> , 2019, 134, 3928-3928.	1.4	3
161	Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients. <i>Blood</i> , 2019, 134, 51-51.	1.4	30
162	The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells. <i>Blood</i> , 2019, 134, 5620-5620.	1.4	3

#	ARTICLE	IF	CITATIONS
163	Systematic Investigation of Microenvironmental Drug Resistance Mechanisms in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3363-3363.	1.4	2
164	Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial. <i>Blood</i> , 2019, 134, 644-644.	1.4	2
165	High Pre-Transplant Free Interleukin-18 Is Associated with Poor Hematopoietic Recovery after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 4507-4507.	1.4	0
166	Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction. <i>Blood</i> , 2019, 134, 4487-4487.	1.4	0
167	The CXCL9 Polymorphism rs884304 Associates with Early CXCL9 Reconstitution and with Severe Chronic Graft-Versus-Host Disease (cGVHD) in Human Allograft Recipients. <i>Blood</i> , 2019, 134, 873-873.	1.4	0
168	High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia. <i>Blood</i> , 2019, 134, 3077-3077.	1.4	0
169	Letermovir Prophylaxis Is Effective for Cytomegalovirus Reactivation after Allogeneic Hematopoietic Cell Transplantation: Single Center Real-World Data. <i>Blood</i> , 2019, 134, 5650-5650.	1.4	0
170	Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 571-571.	1.4	0
171	Biallelic Inactivation of Multiple Tumor Suppressors Is Associated with Early Relapse after Stem Cell Transplant in Newly Diagnosed Myeloma. <i>Blood</i> , 2019, 134, 1783-1783.	1.4	3
172	Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy. <i>Blood</i> , 2019, 134, 3287-3287.	1.4	0
173	High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2018, 180, 840-853.	2.5	15
174	DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. <i>British Journal of Cancer</i> , 2018, 118, 1062-1073.	6.4	30
175	Bone marrow laminins influence hematopoietic stem and progenitor cell cycling and homing to the bone marrow. <i>Matrix Biology</i> , 2018, 67, 47-62.	3.6	37
176	Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1281-1288.	2.0	18
177	Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 37-45.	3.0	24
178	A new option for remission induction in acute myeloid leukaemia. <i>Lancet Oncology</i> , The, 2018, 19, 156-157.	10.7	3
179	Deficiency of the BMP Type I receptor ALK3 partly protects mice from anemia of inflammation. <i>BMC Physiology</i> , 2018, 18, 3.	3.6	5
180	Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 767-776.	1.5	13

#	ARTICLE	IF	CITATIONS
181	An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 510-519.	7.2	7
182	Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?â€”a systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2018, 26, 21-32.	2.2	22
183	Chimeric antigen receptor transduced T cells: Tuning up for the next generation. <i>International Journal of Cancer</i> , 2018, 142, 1738-1747.	5.1	49
184	Single Nucleotide Polymorphisms in CD40L Predict Endothelial Complications and Mortality After Allogeneic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2018, 36, 789-800.	1.6	17
185	Immunosuppressive therapy influences the accelerated age-dependent T-helper cell differentiation in systemic lupus erythematosus remission patients. <i>Arthritis Research and Therapy</i> , 2018, 20, 278.	3.5	10
186	Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack. <i>Haematologica</i> , 2018, 103, 1579-1581.	3.5	1
187	Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. <i>Frontiers in Immunology</i> , 2018, 9, 2207.	4.8	21
188	JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemiaâ€”Letter. <i>Cancer Research</i> , 2018, 78, 6339-6341.	0.9	3
189	The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. <i>Oncotarget</i> , 2018, 7, e1486356.	4.6	14
190	BCR-ABL + acute myeloid leukemia: are we always dealing with a high-risk disease?. <i>Blood Advances</i> , 2018, 2, 1409-1411.	5.2	22
191	Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. <i>Blood Advances</i> , 2018, 2, 2607-2618.	5.2	33
192	<sc>CD</sc>7 is expressed on a subset of normal <sc>CD</sc>34â€”positive myeloid precursors. <i>European Journal of Haematology</i> , 2018, 101, 318-325.	2.2	6
193	Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2018, 52, 1701637.	6.7	7
194	CBFÎ²-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia. <i>Cell</i> , 2018, 174, 172-186.e21.	28.9	68
195	appreci8: a pipeline for precise variant calling integrating 8 tools. <i>Bioinformatics</i> , 2018, 34, 4205-4212.	4.1	26
196	MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia. <i>Cell Death and Disease</i> , 2018, 9, 814.	6.3	23
197	Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. <i>PLoS ONE</i> , 2018, 13, e0200163.	2.5	6
198	Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells. <i>Human Gene Therapy</i> , 2018, 29, 1167-1182.	2.7	19

#	ARTICLE	IF	CITATIONS
199	miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 36.	6.2	16
200	Treatment of AL amyloidosis with bendamustine: a study of 122 patients. <i>Blood</i> , 2018, 132, 1988-1991.	1.4	30
201	IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1695-1707.	4.2	14
202	AL Amyloidosis Pathogenesis and Prognosis Are Determined By the Amyloidogenic Potential of the Light Chain and the Molecular Characteristics of Malignant Plasma Cells. <i>Blood</i> , 2018, 132, 187-187.	1.4	5
203	Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse. <i>Blood</i> , 2018, 132, 253-253.	1.4	11
204	EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1528-1528.	1.4	1
205	Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial. <i>Blood</i> , 2018, 132, 720-720.	1.4	4
206	Characterization of Patients with Multiple Myeloma in Long-Term Remission. <i>Blood</i> , 2018, 132, 4508-4508.	1.4	1
207	Profiling of Oncogenic Signaling in Multiple Myeloma Association with Biology, Disease Progression and Prognosis. <i>Blood</i> , 2018, 132, 3206-3206.	1.4	1
208	Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1461-1461.	1.4	3
209	Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma. <i>Blood</i> , 2018, 132, 254-254.	1.4	14
210	Hematological Malignancies in Adults With a Family Predisposition. <i>Deutsches Arzteblatt International</i> , 2018, 115, 848-854.	0.9	9
211	Outcome of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Beyond First Complete Remission (CR1). <i>Blood</i> , 2018, 132, 4649-4649.	1.4	6
212	Prospective Evaluation of 18-F FDG PET/CT and Biopsies of Osteolytic Lesions and Random Bone Marrow Samples in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2018, 132, 3180-3180.	1.4	1
213	Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal. <i>Blood</i> , 2018, 132, 4485-4485.	1.4	0
214	Genetic Risk of Severe Chronic Graft-Versus-Host Disease Defined By Host-Derived CXCR3 Ligands. <i>Blood</i> , 2018, 132, 357-357.	1.4	0
215	No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy. <i>Blood</i> , 2018, 132, 3399-3399.	1.4	1
216	PPM1D Mutations Are Rare in De Novo and Therapy-Related Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1472-1472.	1.4	2

#	ARTICLE	IF	CITATIONS
217	Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion – a Phase I Study (TOL-1). <i>Blood</i> , 2018, 132, 4539-4539.	1.4	0
218	In Vivo Kinetics of Early, Hypomethylating Agent-Induced Methylome and Transcriptome Changes in Primary AML Blasts: Random or Specific?. <i>Blood</i> , 2018, 132, 3892-3892.	1.4	0
219	Pre-Conditioning Serum Leptin Levels Predict Early Relapse Rates of High Risk AML after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 3419-3419.	1.4	0
220	Inhibition of EZH2 degradation as a novel approach to overcome drug resistance in acute myeloid leukemia. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1291396.	0.7	4
221	Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2017, 31, 549-562.e11.	16.8	89
222	Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. <i>Acta Haematologica</i> , 2017, 137, 163-172.	1.4	10
223	DDX41-related myeloid neoplasia. <i>Seminars in Hematology</i> , 2017, 54, 94-97.	3.4	49
224	Therapy of older persons with acute myeloid leukaemia. <i>Leukemia Research</i> , 2017, 60, 1-10.	0.8	11
225	Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape. <i>Leukemia</i> , 2017, 31, 1640-1644.	7.2	46
226	The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma. <i>Molecular Oncology</i> , 2017, 11, 1288-1301.	4.6	22
227	Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. <i>Nature Medicine</i> , 2017, 23, 69-78.	30.7	192
228	Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus. <i>Blood</i> , 2017, 129, 319-323.	1.4	11
229	Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients. <i>European Journal of Haematology</i> , 2017, 99, 544-552.	2.2	5
230	Relapsed/refractory acute myeloid leukemia: any progress?. <i>Current Opinion in Oncology</i> , 2017, 29, 467-473.	2.4	39
231	Successful collection of peripheral blood stem cells upon VIDE chemomobilization in sarcoma patients. <i>European Journal of Haematology</i> , 2017, 99, 459-464.	2.2	4
232	AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. <i>Nature Cell Biology</i> , 2017, 19, 844-855.	10.3	132
233	Hematopoietic transcription factors and differential cofactor binding regulate PRKACB isoform expression. <i>Oncotarget</i> , 2017, 8, 71685-71698.	1.8	4
234	Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. <i>PLoS ONE</i> , 2017, 12, e0178930.	2.5	18

#	ARTICLE	IF	CITATIONS
235	Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients. <i>Frontiers in Immunology</i> , 2017, 8, 1956.	4.8	79
236	The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial. <i>Blood</i> , 2017, 130, 721-721.	1.4	20
237	Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle Arrest. <i>PLoS ONE</i> , 2017, 12, e0169921.	2.5	11
238	Potential therapeutic impact of CD13 expression in non-small cell lung cancer. <i>PLoS ONE</i> , 2017, 12, e0177146.	2.5	21
239	ABR, a novel inducer of transcription factor C/EBP β , contributes to myeloid differentiation and is a favorable prognostic factor in acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 103626-103639.	1.8	13
240	CBF β -SMMHC Inhibition Disrupts Enhancer Chromatin Dynamics and Represses MYC Transcriptional Program in Inv(16) Leukemia. <i>Blood</i> , 2017, 130, 784-784.	1.4	0
241	Intravenous Iron Carboxymaltose as a Potential Therapeutic in Anemia of Inflammation. <i>PLoS ONE</i> , 2016, 11, e0158599.	2.5	9
242	Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016, 11, e0164587.	2.5	29
243	Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review. <i>Oncology</i> , 2016, 90, 299-306.	1.9	26
244	Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a β 1-integrin-dependent mechanism. <i>International Journal of Cancer</i> , 2016, 138, 964-975.	5.1	20
245	Enteric-coated mycophenolate sodium containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT. <i>European Journal of Haematology</i> , 2016, 97, 232-238.	2.2	6
246	Preclinical Evidence That $^3\text{-Deoxy-}^3\text{-[18F]Fluorothymidine}$ PET Can Visualize Recovery of Hematopoiesis after Gemcitabine Chemotherapy. <i>Cancer Research</i> , 2016, 76, 7089-7095.	0.9	7
247	Real-time two- and three-dimensional imaging of monocyte motility and navigation on planar surfaces and in collagen matrices: roles of Rho. <i>Scientific Reports</i> , 2016, 6, 25016.	3.3	39
248	Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. <i>Leukemia</i> , 2016, 30, 1708-1715.	7.2	38
249	Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. <i>Blood</i> , 2016, 127, 1575-1586.	1.4	38
250	Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors. <i>EMBO Journal</i> , 2016, 35, 2399-2416.	7.8	17
251	Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center. <i>Haematologica</i> , 2016, 101, 1208-1215.	3.5	7
252	Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2905-2915.	4.1	47

#	ARTICLE	IF	CITATIONS
253	Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction. <i>Blood</i> , 2016, 127, 1173-1182.	1.4	83
254	Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (≥60 years). <i>Bone Marrow Transplantation</i> , 2016, 51, 1441-1448.	2.4	37
255	Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown. <i>Nature Protocols</i> , 2016, 11, 22-36.	12.0	39
256	An isoform-specific C/EBP β inhibitor targets acute myeloid leukemia cells. <i>Leukemia</i> , 2016, 30, 1612-1615.	7.2	19
257	Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. <i>Leukemia</i> , 2016, 30, 1230-1236.	7.2	43
258	Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia. <i>Leukemia</i> , 2016, 30, 1781-1784.	7.2	13
259	Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease. <i>Molecular Oncology</i> , 2016, 10, 677-692.	4.6	37
260	Mtss1 is a critical epigenetically regulated tumor suppressor in CML. <i>Leukemia</i> , 2016, 30, 823-832.	7.2	29
261	Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia. <i>Leukemia</i> , 2016, 30, 555-561.	7.2	47
262	Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study. <i>Blood</i> , 2016, 128, 1066-1066.	1.4	5
263	Multi-Genomics of Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia Reveals Three Distinct Genetic Clusters Characterized By Different Alterations. <i>Blood</i> , 2016, 128, 453-453.	1.4	4
264	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. <i>Blood</i> , 2016, 128, 589-589.	1.4	11
265	Diagnostic work-up for the detection of malnutrition in hospitalized cancer patients. <i>Journal of Community and Supportive Oncology</i> , 2016, 14, 155-161.	0.1	4
266	Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. <i>PLoS ONE</i> , 2016, 11, e0160871.	2.5	12
267	A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016, 11, e0164499.	2.5	11
268	Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. <i>Oncotarget</i> , 2016, 7, 82458-82472.	1.8	22
269	Inhibition of IRE1 α -driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 18736-18749.	1.8	71
270	Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling By Suppression of Mir-146a in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1533-1533.	1.4	0

#	ARTICLE	IF	CITATIONS
271	High Expression of ARMCX1 Predicts Poor Survival in Intensively Treated Older Acute Myeloid Leukemia Patients (≥ 60 years). <i>Blood</i> , 2016, 128, 2840-2840.	1.4	0
272	Alarmins MRP8 and MRP14 Induce Stress Tolerance in Phagocytes under Sterile Inflammatory Conditions. <i>Cell Reports</i> , 2015, 11, 849.	6.4	1
273	DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia. <i>Clinical Epigenetics</i> , 2015, 7, 116.	4.1	16
274	Epigenetic dysregulation of K _{Ca} 3.1 channels induces poor prognosis in lung cancer. <i>International Journal of Cancer</i> , 2015, 137, 1306-1317.	5.1	75
275	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. <i>PLoS ONE</i> , 2015, 10, e0136023.	2.5	202
276	Antibody-Mediated Delivery of Anti-KRAS siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1383-1394.	7.0	95
277	PML/RAR α -Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. <i>Cancer Research</i> , 2015, 75, 3411-3424.	0.9	39
278	5-Azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation. <i>International Journal of Oncology</i> , 2015, 46, 1192-1204.	3.3	30
279	Allogeneic Stem-Cell Transplantation in Patients With NPM1-Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 403-410.	1.6	74
280	MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML. <i>Experimental Hematology</i> , 2015, 43, 794-802.e4.	0.4	19
281	Facing the Challenges of Chronic Pruritus: A Report From a Multi-disciplinary Medical Itch Centre in Germany. <i>Acta Dermato-Venereologica</i> , 2015, 95, 266-271.	1.3	42
282	Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic Meningitis. <i>Oncology</i> , 2015, 89, 137-142.	1.9	16
283	Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. <i>Cancer Cell</i> , 2015, 27, 658-670.	16.8	341
284	Trabectedin: Supportive care strategies and safety profile. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 279-290.	4.4	15
285	Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 485-492.	2.4	25
286	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1691-1699.	10.7	347
287	Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor. <i>Journal of Ultrasound in Medicine</i> , 2015, 34, 1227-1236.	1.7	11
288	Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2015, 21, 4935-4946.	7.0	68

#	ARTICLE	IF	CITATIONS
289	NF- κ B/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. <i>Leukemia</i> , 2015, 29, 535-547.	7.2	120
290	Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0125783.	2.5	23
291	A Limited Role for the Cell Cycle Regulator Cyclin A1 in Murine Leukemogenesis. <i>PLoS ONE</i> , 2015, 10, e0129147.	2.5	1
292	The Indications for Allogeneic Stem Cell Transplantation in Myeloid Malignancies. <i>Deutsches Arzteblatt International</i> , 2015, 112, 262-70.	0.9	14
293	Abstract 4430: Loss of the histone methyltransferase EZH2 induces chemoresistance in acute myeloid leukemia (AML). , 2015, , .		0
294	Allogeneic Stem Cell Transplantation (SCT) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) in Elderly Patients (Older than 60 Years). <i>Blood</i> , 2015, 126, 2025-2025.	1.4	0
295	Proteinase-Activated Receptor 1 (PAR1) Regulates Leukemic Stem Cell Functions. <i>PLoS ONE</i> , 2014, 9, e94993.	2.5	11
296	Alarmins MRP8 and MRP14 Induce Stress Tolerance in Phagocytes under Sterile Inflammatory Conditions. <i>Cell Reports</i> , 2014, 9, 2112-2123.	6.4	118
297	Neuropharmacology and Management of Chemotherapy-Induced Nausea and Vomiting in Patients with Breast Cancer. <i>Breast Care</i> , 2014, 9, 246-253.	1.4	9
298	DNA Methyltransferase Inhibition Reverses Epigenetically Embedded Phenotypes in Lung Cancer Preferentially Affecting Polycomb Target Genes. <i>Clinical Cancer Research</i> , 2014, 20, 814-826.	7.0	45
299	Prognostic Impact of Bcl-2 Depends on Tumor Histology and Expression of MALAT-1 lncRNA in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1294-1304.	1.1	59
300	Treatment of rare co-occurrence of Epstein-Barr virus-driven post-transplant lymphoproliferative disorder and hemophagocytic lymphohistiocytosis after allogeneic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2014, 16, 988-992.	1.7	11
301	Origins of aberrant DNA methylation in acute myeloid leukemia. <i>Leukemia</i> , 2014, 28, 1-14.	7.2	112
302	Allogeneic Transplantation Versus Chemotherapy as Postremission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 288-296.	1.6	88
303	Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use. <i>British Journal of Haematology</i> , 2014, 165, 17-38.	2.5	76
304	Molecular monitoring in NUP214-ABL-positive T-acute lymphoblastic leukemia reveals clonal diversity and helps to guide targeted therapy. <i>Leukemia</i> , 2014, 28, 419-422.	7.2	7
305	Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 18 F-Fluorothymidine PET and Diffusion-Weighted MR Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 983-988.	5.0	21
306	Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. <i>Blood</i> , 2014, 124, 1426-1433.	1.4	204

#	ARTICLE	IF	CITATIONS
307	Abstract 510: Inhibition of IRE1-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. , 2014, , .		3
308	DDX41 Is a Tumor Suppressor Gene Associated with Inherited and Acquired Mutations. Blood, 2014, 124, 125-125.	1.4	1
309	Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soramf Trial. Blood, 2014, 124, 6-6.	1.4	34
310	Feasibility of BIBF1120 (nintedanib) combined with low-dose cytarabine in elderly patients with AML ineligible for intensive treatment.. Journal of Clinical Oncology, 2014, 32, 7053-7053.	1.6	1
311	Maintenance of Leukemia-Initiating Cells Is Regulated by the CDK Inhibitor Inca1. PLoS ONE, 2014, 9, e115578.	2.5	3
312	The G-CSF Induced MiR-143 Targets MAPK-Family Proteins and Is a Prognostic Factor for RIC-Transplanted AML Patients. Blood, 2014, 124, 2200-2200.	1.4	2
313	The PML/RAR-Regulated MiR-181a/b-Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Blood, 2014, 124, 2195-2195.	1.4	0
314	PML-RAR Repressed MicroRNA 126 Mediates Differentiation in Acute Promyelocytic Leukemia By Targeting the Protooncogene C-Myb. Blood, 2014, 124, 3558-3558.	1.4	0
315	Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL). Blood, 2014, 124, 946-946.	1.4	4
316	In Vivo Methylome Changes in Purified Peripheral Blood Blasts and T Cells of AML Patients Treated with Decitabine: Statistical Modelling of a Hypomethylation Response. Blood, 2014, 124, 870-870.	1.4	0
317	DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Annals of Hematology, 2013, 92, 1041-1048.	1.8	15
318	Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Annals of Hematology, 2013, 92, 41-52.	1.8	53
319	Anticancer Therapy by Tumor Vessel Infarction with Polyethylene Glycol Conjugated Retargeted Tissue Factor. Journal of Medicinal Chemistry, 2013, 56, 2337-2347.	6.4	26
320	Transcription factor C/EBP-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia. Blood, 2013, 122, 2433-2442.	1.4	33
321	Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology, 2013, 31, 3110-3118.	1.6	290
322	DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding. Blood, 2013, 121, 178-187.	1.4	61
323	Lats 1 is a putative tumor suppressor in Hoxa9 / Meis induced leukemia. Experimental Hematology, 2013, 41, S20.	0.4	0
324	CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. Bone Marrow Transplantation, 2013, 48, 1070-1076.	2.4	43

#	ARTICLE	IF	CITATIONS
325	The Role of Human Equilibrative Nucleoside Transporter 1 on the Cellular Transport of the DNA Methyltransferase Inhibitors 5-Azacytidine and CP-4200 in Human Leukemia Cells. <i>Molecular Pharmacology</i> , 2013, 84, 438-450.	2.3	45
326	A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Bcr-Abl tyrosine kinase inhibitor imatinib in elderly patients with refractory/relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013, 163, 214-222.	2.5	36
327	ERG Transcriptional Networks in Primary Acute Leukemia Cells Implicate a Role for ERG in Deregulated Kinase Signaling. <i>PLoS ONE</i> , 2013, 8, e52872.	2.5	13
328	Knockdown Of The Piwi - Like Protein 4 (PIWIL4) Delays Leukemic Growth and Is Associated With Gross Changes In The Global Histone Methylation Marks In Human MLL - Rearranged AML. <i>Blood</i> , 2013, 122, 597-597.	1.4	3
329	Hematopoietic Sphingosine 1-Phosphate Lyase Deficiency Decreases Atherosclerotic Lesion Development in LDL-Receptor Deficient Mice. <i>PLoS ONE</i> , 2013, 8, e63360.	2.5	26
330	The limited contribution of DNA methylation to PML-RAR α induced leukemia. <i>Oncotarget</i> , 2013, 4, 5-6.	1.8	4
331	Loss Of H3K27 Trimethylation (H3K27me3) Associates With a Multi Drug Resistance Phenotype In Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 1253-1253.	1.4	0
332	Identification Of Leukemia Suppressive Genes By Inducible Overexpression Of The DNA Methyltransferase DNMT3B During Leukemogenesis In Mice. <i>Blood</i> , 2013, 122, 2493-2493.	1.4	0
333	In Vivo RNAi Screening Identifies HDAC4 As a Mediator Of Chemoresistance In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1257-1257.	1.4	0
334	Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity. <i>Blood</i> , 2013, 122, 1447-1447.	1.4	0
335	Ubiquitously Expressed Major Histocompatibility (MHC) Class I and Minor Histocompatibility Alloantigens (mHAg) Are No Relevant Targets For Graft-Versus-Tumor (GvT) Reactions In Mice After Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 2013, 122, 3249-3249.	1.4	0
336	Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. <i>Annals of Oncology</i> , 2012, 23, 990-996.	1.2	36
337	Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1577-1585.	1.3	26
338	High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases. <i>Bone Marrow Transplantation</i> , 2012, 47, 1321-1325.	2.4	3
339	Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1062-1067.	1.3	23
340	Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-I. <i>Leukemia</i> , 2012, 26, 615-622.	7.2	39
341	Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. <i>Blood</i> , 2012, 119, 5215-5220.	1.4	54
342	Integrative Analyses for Omics Data: A Bayesian Mixture Model to Assess the Concordance of ChIP-chip and ChIP-seq Measurements. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2012, 75, 461-470.	2.3	15

#	ARTICLE	IF	CITATIONS
343	Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML. <i>Leukemia</i> , 2012, 26, 1030-1037.	7.2	29
344	A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies. <i>Haematologica</i> , 2012, 97, 1380-1388.	3.5	20
345	SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control. <i>Blood</i> , 2012, 120, 1691-1702.	1.4	27
346	Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling. <i>Cellular Signalling</i> , 2012, 24, 2095-2101.	3.6	31
347	Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. <i>Blood</i> , 2012, 119, 2346-2357.	1.4	72
348	Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression. <i>Cell Communication and Signaling</i> , 2012, 10, 19.	6.5	38
349	Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells. <i>PLoS ONE</i> , 2012, 7, e40853.	2.5	21
350	POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience. <i>Annals of Hematology</i> , 2012, 91, 1419-1425.	1.8	6
351	Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. <i>Nature Medicine</i> , 2012, 18, 605-611.	30.7	584
352	STEAP1 Is Associated with the Invasive and Oxidative Stress Phenotype of Ewing Tumors. <i>Molecular Cancer Research</i> , 2012, 10, 52-65.	3.4	109
353	Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. <i>Blood</i> , 2012, 119, 1501-1510.	1.4	359
354	C/EBP β mediates nicotinamide-enhanced clearance of <i>Staphylococcus aureus</i> in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 3316-3329.	8.2	62
355	Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients \geq 60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial. <i>Blood</i> , 2012, 120, 144-144.	1.4	4
356	Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment. <i>Blood</i> , 2012, 120, 411-411.	1.4	10
357	Leukemia Gene Atlas $\hat{=}$ A Public Platform for Integrative Exploration of Genome-Wide Molecular Data. <i>PLoS ONE</i> , 2012, 7, e39148.	2.5	47
358	Mutations of the EPHB6 Receptor Tyrosine Kinase Induce a Pro-Metastatic Phenotype in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2012, 7, e44591.	2.5	21
359	Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia $\hat{=}$ A Randomised SAL Pilot Study. <i>PLoS ONE</i> , 2012, 7, e52695.	2.5	25
360	Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis. <i>Blood</i> , 2012, 120, 1974-1974.	1.4	0

#	ARTICLE	IF	CITATIONS
361	A Specific DNA Methylation Pattern Is Associated with Delayed Leukemogenesis and Altered Response to Chemotherapeutic Treatment in an Inducible DNMT3b Expressing Mouse Model. <i>Blood</i> , 2012, 120, 398-398.	1.4	0
362	C/EBP β mediates nicotinamide-enhanced clearance of <i>Staphylococcus aureus</i> in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 4301-4301.	8.2	0
363	DNA Methyltransferase 3B (DNMT3B) Protein Expression Predicts Survival in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012, 120, 1395-1395.	1.4	0
364	Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation. <i>Blood</i> , 2012, 120, 2776-2776.	1.4	1
365	Mechanism of action of demethylating and immune modulatory agents – Introduction. <i>Cancer Treatment Reviews</i> , 2011, 37, S1.	7.7	0
366	Mechanism of action of demethylating and immune modulatory agents – Conclusion. <i>Cancer Treatment Reviews</i> , 2011, 37, S23-S24.	7.7	0
367	DNA methylation as a pathogenic event and as a therapeutic target in AML. <i>Cancer Treatment Reviews</i> , 2011, 37, S13-S18.	7.7	41
368	The Inhibitor of Growth Protein 5 (ING5) Depends on INCA1 as a Co-Factor for Its Antiproliferative Effects. <i>PLoS ONE</i> , 2011, 6, e21505.	2.5	27
369	Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. <i>Blood</i> , 2011, 117, 2935-2943.	1.4	76
370	AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein. <i>Blood</i> , 2011, 117, 4328-4337.	1.4	34
371	Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. <i>Haematologica</i> , 2011, 96, 972-979.	3.5	58
372	Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein β from hematopoietic cells in a family with AML. <i>Leukemia</i> , 2011, 25, 1209-1210.	7.2	31
373	miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. <i>Experimental Hematology</i> , 2011, 39, 1030-1042.e7.	0.4	43
374	HIS-based Kaplan-Meier plots - a single source approach for documenting and reusing routine survival information. <i>BMC Medical Informatics and Decision Making</i> , 2011, 11, 11.	3.0	15
375	Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B \times ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma. <i>American Journal of Hematology</i> , 2011, 86, E61-4.	4.1	22
376	Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. <i>Leukemia Research</i> , 2011, 35, 620-625.	0.8	28
377	Apolipoprotein E Induces Antiinflammatory Phenotype in Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1160-1168.	2.4	257
378	Inhibitor of Cyclin-dependent Kinase (CDK) Interacting with Cyclin A1 (INCA1) Regulates Proliferation and Is Repressed by Oncogenic Signaling. <i>Journal of Biological Chemistry</i> , 2011, 286, 28210-28222.	3.4	17

#	ARTICLE	IF	CITATIONS
379	The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1984-1992.	1.1	515
380	Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML. <i>Blood</i> , 2011, 118, 1549-1549.	1.4	16
381	The Treatment of Elderly Patients With Acute Myeloid Leukemia. <i>Deutsches A&#x0308;rztblatt International</i> , 2011, 108, 863-70.	0.9	43
382	Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial. <i>Blood</i> , 2011, 118, 2773-2773.	1.4	0
383	Histone H3 Methylation Mediates All-Trans-Retinoic Acid Responsiveness in Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 224-224.	1.4	0
384	Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review). <i>Oncology Reports</i> , 2010, 23, 595-604.	2.6	7
385	Low SMC1A protein expression predicts poor survival in acute myeloid leukemia. <i>Oncology Reports</i> , 2010, 24, 47-56.	2.6	16
386	Pim2 cooperates with PML-RAR α to induce acute myeloid leukemia in a bone marrow transplantation model. <i>Blood</i> , 2010, 115, 4507-4516.	1.4	12
387	BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. <i>Blood</i> , 2010, 115, 3185-3195.	1.4	85
388	Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome α -negative myeloproliferative neoplasms. <i>Blood</i> , 2010, 115, 2882-2890.	1.4	116
389	Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. <i>Blood</i> , 2010, 115, 1768-1778.	1.4	265
390	Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. <i>Blood</i> , 2010, 116, 3564-3571.	1.4	90
391	C/EBP β regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBA mutations. <i>Blood</i> , 2010, 116, 5638-5649.	1.4	119
392	Combination of romiplostim and rituximab: effective therapy of severe immune thrombocytopenia. <i>European Journal of Haematology</i> , 2010, 84, 362-364.	2.2	6
393	Prognostic Stratification For Curatively Resected NSCLC Patients By Apoptosis Panel. , 2010, , .		0
394	The EPHB6 Receptor Tyrosine Kinase Is a Metastasis Suppressor That Is Frequently Silenced by Promoter DNA Hypermethylation in Non α -Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2275-2283.	7.0	73
395	Routine data from hospital information systems can support patient recruitment for clinical studies. <i>Clinical Trials</i> , 2010, 7, 183-189.	1.6	56
396	Evaluating oligonucleotide properties for DNA microarray probe design. <i>Nucleic Acids Research</i> , 2010, 38, e121-e121.	14.5	11

#	ARTICLE	IF	CITATIONS
397	Norepinephrine and Serotonin Transporter Genes: Impact on Treatment Response in Depression. <i>Neuropsychobiology</i> , 2010, 62, 121-131.	1.9	63
398	Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia. <i>Journal of Clinical Oncology</i> , 2010, 28, 4333-4338.	1.6	67
399	Keratinocytes Determine Th1 Immunity during Early Experimental Leishmaniasis. <i>PLoS Pathogens</i> , 2010, 6, e1000871.	4.7	63
400	Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. <i>Lancet</i> , 2010, 376, 2000-2008.	13.7	290
401	Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine. <i>Blood</i> , 2010, 116, 3316-3316.	1.4	13
402	Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial. <i>Blood</i> , 2010, 116, 333-333.	1.4	24
403	Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C Plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 335-335.	1.4	7
404	SOCS1 Cooperates with FLT3-ITD In the Development of Myeloproliferative Disease by Promoting the Escape From External Cytokine Control.. <i>Blood</i> , 2010, 116, 1054-1054.	1.4	0
405	Older Patients with Normal Cytogenetics AML Have a Higher Rate of Genomic Changes Compared to Young Patients as Determined by SNP Chip Analysis. <i>Blood</i> , 2010, 116, 2479-2479.	1.4	0
406	Genome Wide Screening Reveals Distinct Signaling Pathways of the ETS Transcription Factor ERG In Primary Acute Leukemia Blasts. <i>Blood</i> , 2010, 116, 4184-4184.	1.4	0
407	Estimating the Chances of Older AML Patients to Achieve a Complete Remission Upon Intensive Induction Chemotherapy - An AMLCG and SAL Study. <i>Blood</i> , 2010, 116, 2696-2696.	1.4	0
408	Construction and Application of an Inducible System for Homogenous Expression Levels in Bulk Cell Lines. <i>PLoS ONE</i> , 2009, 4, e6445.	2.5	4
409	EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5324-5329.	7.1	260
410	S100A2 Induces Metastasis in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 22-29.	7.0	99
411	Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 61-69.	1.6	315
412	Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2. <i>Cell Cycle</i> , 2009, 8, 1991-1996.	2.6	71
413	Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3-Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 520-531.	7.0	28
414	Hereditary thrombocytopenia and acute myeloid leukemia: a common link due to a germline mutation in the AML1 gene. <i>Annals of Hematology</i> , 2009, 88, 1037-1038.	1.8	8

#	ARTICLE	IF	CITATIONS
415	Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes. <i>Molecular Cell</i> , 2009, 36, 326-339.	9.7	278
416	The kinase defective EPHB6 receptor tyrosine kinase activates MAP kinase signaling in lung adenocarcinoma. <i>International Journal of Oncology</i> , 2009, 35, 175-9.	3.3	9
417	E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. <i>Blood</i> , 2009, 114, 4197-4208.	1.4	44
418	Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial. <i>Blood</i> , 2009, 114, 485-485.	1.4	4
419	Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer. <i>Anticancer Research</i> , 2009, 29, 1157-62.	1.1	14
420	Identification of acute myeloid leukaemia associated microRNA expression patterns. <i>British Journal of Haematology</i> , 2008, 140, 153-161.	2.5	72
421	Solitary plasmacytoma of the lung with coexisting sarcoid-like lesions. <i>Annals of Hematology</i> , 2008, 87, 417-420.	1.8	4
422	Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia. <i>International Journal of Hematology</i> , 2008, 88, 174-180.	1.6	11
423	Workflow to improve patient recruitment for clinical trials within hospital information systems - a case-study. <i>Trials</i> , 2008, 9, 2.	1.6	34
424	Advances in the treatment of acute myeloid leukemia: From chromosomal aberrations to biologically targeted therapy. <i>Journal of Cellular Biochemistry</i> , 2008, 104, 2059-2070.	2.6	22
425	Amsacrine containing induction therapy in elderly AML patients: Comparison to standard induction regimens in a matched-pair analysis. <i>Leukemia Research</i> , 2008, 32, 491-494.	0.8	14
426	Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation. <i>Leukemia</i> , 2008, 22, 78-86.	7.2	29
427	Activation of counter-regulatory mechanisms in a rat renal acute rejection model. <i>BMC Genomics</i> , 2008, 9, 71.	2.8	24
428	Characterization of the Ca ²⁺ -regulated Ezrin-S100P Interaction and Its Role in Tumor Cell Migration. <i>Journal of Biological Chemistry</i> , 2008, 283, 29331-29340.	3.4	68
429	Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants. <i>Nucleic Acids Research</i> , 2008, 36, 5362-5375.	14.5	50
430	Splenic Marginal Zone Lymphoma: Transformation to Diffuse Large B-Cell Lymphoma With Isolated Cerebral Manifestation. <i>Journal of Clinical Oncology</i> , 2008, 26, 4509-4511.	1.6	8
431	Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. <i>Annals of Oncology</i> , 2008, 19, 1644-1649.	1.2	35
432	Adjuvant Therapy with Small Hairpin RNA Interference Prevents Non-Small Cell Lung Cancer Metastasis Development in Mice. <i>Cancer Research</i> , 2008, 68, 1896-1904.	0.9	32

#	ARTICLE	IF	CITATIONS
433	The Absence of Cutaneous Lymph Nodes Results in a Th2 Response and Increased Susceptibility to <i>Leishmania major</i> Infection in Mice. <i>Infection and Immunity</i> , 2008, 76, 4241-4250.	2.2	26
434	Chromatin modifications induced by PML-RAR α repress critical targets in leukemogenesis as analyzed by ChIP-Chip. <i>Blood</i> , 2008, 111, 2887-2895.	1.4	73
435	The hidden faces of C/EBP β . <i>Blood</i> , 2008, 111, 2949-2950.	1.4	0
436	Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial. <i>Blood</i> , 2008, 112, 2973-2973.	1.4	8
437	Chemotherapy in metastatic malignant triton tumor: Report on two cases. <i>Oncology Reports</i> , 2007, 18, 763-7.	2.6	15
438	DNA Methylation of Tumor Suppressor Genes in Clinical Remission Predicts the Relapse Risk in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2007, 67, 1370-1377.	0.9	89
439	Activation mechanisms of STAT5 by oncogenic Flt3-ITD. <i>Blood</i> , 2007, 110, 370-374.	1.4	170
440	Flt3-dependent transformation by inactivating c-Cbl mutations in AML. <i>Blood</i> , 2007, 110, 1004-1012.	1.4	177
441	CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer-binding protein alpha. <i>Blood</i> , 2007, 110, 3695-3705.	1.4	50
442	The C/EBP β tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. <i>Blood</i> , 2007, 109, 3895-3905.	1.4	115
443	Heparin-Induced Thrombocytopenia vs. Plasmapheresis- Induced Platelet Loss in a Case of Thrombotic Thrombocytopenic Purpura. <i>Transfusion Medicine and Hemotherapy</i> , 2007, 34, 74-77.	1.6	2
444	DNA damage response involves modulation of Ku70 and Rb functions by cyclin A1 in leukemia cells. <i>International Journal of Cancer</i> , 2007, 121, 706-713.	5.1	13
445	The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. <i>Leukemia</i> , 2007, 21, 1638-1647.	7.2	101
446	Analysis of the genetic interactions between Cyclin A1, Atm and p53 during spermatogenesis. <i>Asian Journal of Andrology</i> , 2007, 9, 739-750.	1.6	9
447	New Molecular Therapy Targets in Acute Myeloid Leukemia. <i>Recent Results in Cancer Research</i> , 2007, 176, 243-262.	1.8	6
448	Defining the Leukemia Epigenome: Distinct Genome Wide Histone H3 Modification Patterns Exist in AML, ALL and Healthy Hematopoietic Progenitor Cells.. <i>Blood</i> , 2007, 110, 2124-2124.	1.4	0
449	The Cyclin Interactor p26INCA1 Regulates the Hematopoietic Stem Cell Pool Via CDK Inhibition.. <i>Blood</i> , 2007, 110, 637-637.	1.4	0
450	Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3105-3112.	4.1	26

#	ARTICLE	IF	CITATIONS
451	Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups. <i>Blood</i> , 2006, 107, 2079-2089.	1.4	34
452	Proteomic analysis of acute promyelocytic leukemia: PML-RAR α leads to decreased phosphorylation of OP18 at serine 63. <i>Proteomics</i> , 2006, 6, 5705-5719.	2.2	13
453	Wnt signaling regulates transendothelial migration of monocytes. <i>Journal of Leukocyte Biology</i> , 2006, 79, 1306-1313.	3.3	60
454	Emerging Flt3 kinase inhibitors in the treatment of leukaemia. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 153-165.	2.4	21
455	Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy. <i>World Journal of Gastroenterology</i> , 2006, 12, 3297.	3.3	53
456	Distinct Expression Patterns of Human microRNAs in Myeloid Differentiation and Acute Myeloid Leukemia.. <i>Blood</i> , 2006, 108, 2231-2231.	1.4	0
457	Decitabine and Vitamin D3 Differentially Increase C-Jun, PU.1, and Sp1 Hematopoietic Transcription Factors To Induce Monocytic Differentiation.. <i>Blood</i> , 2006, 108, 2223-2223.	1.4	1
458	Activation Mechanisms of STAT5 by Oncogenic Flt3-ITD.. <i>Blood</i> , 2006, 108, 1435-1435.	1.4	27
459	Constitutive Activation of Akt by Flt3 Internal Tandem Duplications Is Necessary for Increased Survival, Proliferation, and Myeloid Transformation. <i>Cancer Research</i> , 2005, 65, 9643-9650.	0.9	205
460	Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. <i>Blood</i> , 2005, 105, 3699-3706.	1.4	99
461	AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. <i>Blood</i> , 2005, 106, 265-273.	1.4	224
462	RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. <i>Blood</i> , 2005, 105, 2107-2114.	1.4	70
463	Signal Transduction of Oncogenic Flt3. <i>International Journal of Hematology</i> , 2005, 82, 93-99.	1.6	77
464	The synthetic furanonaphthoquinone induces growth arrest, apoptosis and differentiation in a variety of leukaemias and multiple myeloma cells. <i>British Journal of Haematology</i> , 2005, 131, 520-529.	2.5	14
465	Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells. <i>Oncogene</i> , 2005, 24, 2739-2744.	5.9	82
466	Expression patterns of mitotic and meiotic cell cycle regulators in testicular cancer and development. <i>International Journal of Cancer</i> , 2005, 116, 207-217.	5.1	21
467	The molecular pathogenesis of acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 195-221.	4.4	63
468	Alterations of Lymphoid Enhancer Factor-1 Isoform Expression in Solid Tumors and Acute Leukemias. <i>Acta Biochimica Et Biophysica Sinica</i> , 2005, 37, 173-180.	2.0	21

#	ARTICLE	IF	CITATIONS
469	In vivo analyses of UV-irradiation-induced p53 promoter binding using a novel quantitative real-time PCR assay. <i>International Journal of Oncology</i> , 2005, 26, 493.	3.3	0
470	Identification of Metastasis-Associated Receptor Tyrosine Kinases in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2005, 65, 1778-1782.	0.9	124
471	Alterations of Lymphoid Enhancer Factor-1 Isoform Expression in Solid Tumors and Acute Leukemias. <i>Acta Biochimica Et Biophysica Sinica</i> , 2005, 37, 173-180.	2.0	2
472	Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias. <i>Acta Biochimica Et Biophysica Sinica</i> , 2005, 37, 173-80.	2.0	9
473	First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer. <i>Oncology Reports</i> , 2005, 14, 1539-42.	2.6	4
474	S100 Family Members and Trypsinogens Are Predictors of Distant Metastasis and Survival in Early-Stage Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2004, 64, 5564-5569.	0.9	169
475	The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 6478-6483.	7.1	189
476	Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells. <i>Molecular and Cellular Biology</i> , 2004, 24, 2890-2904.	2.3	280
477	The Cyclin A1-CDK2 Complex Regulates DNA Double-Strand Break Repair. <i>Molecular and Cellular Biology</i> , 2004, 24, 8917-8928.	2.3	106
478	Identification of Interaction Partners and Substrates of the Cyclin A1-CDK2 Complex. <i>Journal of Biological Chemistry</i> , 2004, 279, 33727-33741.	3.4	59
479	Expression of SOCS-1, Suppressor of Cytokine Signalling-1, in Human Melanoma. <i>Journal of Investigative Dermatology</i> , 2004, 123, 737-745.	0.7	68
480	Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemia. <i>Leukemia</i> , 2004, 18, 720-726.	7.2	25
481	The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RAR α and regulates differentiation of hematopoietic cells. <i>Oncogene</i> , 2004, 23, 9162-9172.	5.9	30
482	Epigenetic regulation of tumor suppressors in t(8:21)-containing AML. <i>Annals of Hematology</i> , 2004, 83, 329-330.	1.8	6
483	Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy. <i>Leukemia Research</i> , 2004, 28, 1069-1074.	0.8	39
484	Genome-wide screening for prognosis-predicting genes in early-stage non-small-cell lung cancer. <i>Lung Cancer</i> , 2004, 45, S145-S150.	2.0	35
485	High-Throughput Analysis of Genome-Wide Receptor Tyrosine Kinase Expression in Human Cancers Identifies Potential Novel Drug Targets. <i>Clinical Cancer Research</i> , 2004, 10, 1241-1249.	7.0	107
486	Flt3 Internal Tandem Duplications Cooperate with Wnt Signaling in Leukemic Signal Transduction. <i>Blood</i> , 2004, 104, 822-822.	1.4	10

#	ARTICLE	IF	CITATIONS
487	Constitutive Activation of Akt and mTOR by Flt3 Internal Tandem Duplications Mediates Myeloid Leukemogenesis and Can Be Inhibited by Rapamycin.. Blood, 2004, 104, 2532-2532.	1.4	8
488	Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia. British Journal of Haematology, 2003, 123, 413-419.	2.5	40
489	MALAT-1, a novel noncoding RNA, and thymosin β 4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene, 2003, 22, 8031-8041.	5.9	1,986
490	Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood, 2003, 101, 3164-3173.	1.4	274
491	Cyclin A1 is highly expressed in aggressive testicular germ cell tumors. Cancer Letters, 2003, 190, 89-95.	7.2	38
492	E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Review of Molecular Diagnostics, 2003, 3, 617-633.	3.1	66
493	Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8448-8453.	7.1	17
494	Redirection of Oncoproteins to Kill Cancer Cells. Cell Cycle, 2003, 2, 531-533.	2.6	0
495	Successive increases in human cyclin A1 promoter activity during spermatogenesis in transgenic mice. International Journal of Molecular Medicine, 2003, 11, 311.	4.0	1
496	Successive increases in human cyclin A1 promoter activity during spermatogenesis in transgenic mice. International Journal of Molecular Medicine, 2003, 11, 311-5.	4.0	6
497	Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells. International Journal of Oncology, 2003, 23, 151-8.	3.3	2
498	Cyclin A1 and gametogenesis in fertile and infertile patients: a potential new molecular diagnostic marker. Human Reproduction, 2002, 17, 2338-2343.	0.9	23
499	Quantification of cyclin A1 and glyceraldehyde-3-phosphate dehydrogenase expression in testicular biopsies of infertile patients by fluorescence real-time RT-PCR. Journal of Developmental and Physical Disabilities, 2002, 25, 202-209.	3.6	5
500	Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia, 2002, 16, 1302-1310.	7.2	181
501	The t(8;21) fusion protein, AML1-ETO, specifically represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia. Nature Medicine, 2002, 8, 743-750.	30.7	258
502	Analyses of the genomic methylation status of the human cyclin A1 promoter by a novel real-time PCR-based methodology. FEBS Letters, 2001, 490, 75-78.	2.8	18
503	Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function. Blood, 2001, 97, 2091-2097.	1.4	55
504	Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer. British Journal of Cancer, 2001, 85, 1168-1174.	6.4	12

#	ARTICLE	IF	CITATIONS
505	Cyr61, a Member of CCN Family, Is a Tumor Suppressor in Non-Small Cell Lung Cancer. Journal of Biological Chemistry, 2001, 276, 47709-47714.	3.4	118
506	First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer. Oncology Reports, 0, , .	2.6	2